Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
149.21B
Market cap149.21B
Price-Earnings ratio
20.07
Price-Earnings ratio20.07
Dividend yield
6.57%
Dividend yield6.57%
Average volume
33.24M
Average volume33.24M
High today
$26.22
High today$26.22
Low today
$25.93
Low today$25.93
Open price
$26.19
Open price$26.19
Volume
48.28M
Volume48.28M
52 Week high
$28.75
52 Week high$28.75
52 Week low
$23.06
52 Week low$23.06

Stock Snapshot

The current Pfizer(PFE) stock price is $26.14, with a market capitalization of 149.21B. The stock trades at a price-to-earnings (P/E) ratio of 20.07 and offers a dividend yield of 6.6%.

On 2026-05-31, Pfizer(PFE) stock traded between a low of $25.93 and a high of $26.22. Shares are currently priced at $26.14, which is +0.8% above the low and -0.3% below the high.

The Pfizer(PFE)'s current trading volume is 48.28M, compared to an average daily volume of 33.24M.

In the last year, Pfizer(PFE) shares hit a 52-week high of $28.75 and a 52-week low of $23.06.

In the last year, Pfizer(PFE) shares hit a 52-week high of $28.75 and a 52-week low of $23.06.

PFE News

TipRanks 8h
Pfizer announces results from Cohort 3 on Bratovi with cetuximab, Folfiri

Pfizer (PFE) announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 Breakwater trial, evaluating Bra...

Barchart 13h
How Is Pfizer's Stock Performance Compared to Other Healthcare Stocks? - Barchart

...

How Is Pfizer's Stock Performance Compared to Other Healthcare Stocks? - Barchart
Nasdaq 1d
Why Wall Street Is Dead Wrong About This Popular Stock

Key Points Pfizer is dealing with what are really just normal headwinds for a drug company. Although the near term is likely to be challenging, a material sto...

Why Wall Street Is Dead Wrong About This Popular Stock

Analyst ratings

55%

of 29 ratings
Buy
34.5%
Hold
55.2%
Sell
10.3%

More PFE News

TipRanks 1d
Pfizer Pivots to Obesity and Oncology as Wall Street Waits

Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Memorial Day Sale – Claim 70% Off TipRanks Unlock tr...

Simply Wall St 2d
Pfizer’s US$10.5b Oncology Deal With Innovent And What It Means For Valuation

Pfizer (NYSE:PFE) has agreed a global oncology partnership with Innovent Biologics valued at up to $10.5b. The alliance gives Pfizer access to 12 early stage c...

Pfizer’s US$10.5b Oncology Deal With Innovent And What It Means For Valuation
TipRanks 2d
Pfizer’s VESPER-4 Obesity Trial Signals a Serious Push Into the GLP-1 Growth Market

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings a...

TipRanks 2d
Pfizer’s Real-World Lung Cancer Study on Dacomitinib: What Investors Should Know

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings a...

Benzinga 3d
Pfizer Strikes Up To $10.5 Billion Deal With China's Innovent Biologics To Develop Next-Gen Cancer Therapies

The agreement comprises an upfront payment of $650 million to Innovent, with potential development, regulatory, and commercial milestone payments reaching up to...

Pfizer Strikes Up To $10.5 Billion Deal With China's Innovent Biologics To Develop Next-Gen Cancer Therapies
Seeking Alpha 3d
Pfizer signs up to $10.5B oncology deal with China’s Innovent

Pfizer (PFE) and Innovent Biologics (IVBIY) (IVBXF) have entered into a global oncology partnership worth up to $10.5B, underscoring growing demand among multin...

Pfizer signs up to $10.5B oncology deal with China’s Innovent
Simply Wall St 3d
Should Pfizer’s New 25‑Valent Vaccine Data and Oncology Alliance Require Action From Investors?

In May 2026, Sarah Cannon Research Institute announced a collaboration with Pfizer to accelerate development of Pfizer’s oncology portfolio using SCRI’s Acceler...

Should Pfizer’s New 25‑Valent Vaccine Data and Oncology Alliance Require Action From Investors?

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.